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evised manuscript received September 13, 2013,(1). Clopidogrel monotherapy is recommended for patients
with peripheral arterial disease (PAD), and a combination of
aspirin and clopidogrel may be prescribed for patients “who
are not at increased risk of bleeding and who are at high
perceived cardiovascular risk” (2). Guidelines recommend
the use of combination antiplatelet therapy with clopidogrel
and aspirin for patients with acute coronary syndromes and
for patients undergoing coronary artery stenting for 1 year
(3–5). Recently, a number of large studies have highlighted
increased morbidity and mortality after planned cessation of
clopidogrel therapy in these patients (6–8).
It has been postulated that the increase in thrombotic
events could be due to a rebound in platelet activity (9,10).
However, in previous studies (11–13), platelet activity
before commencing clopidogrel was not assessed, and there-
fore, it is unclear whether platelet activity after withdrawal
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ADP = adenosine
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234was any higher than pre-treatment
levels. The implications of a pos-
sible rebound effect are clearly
important (14,15), and we aimed
to determine whether a course
of clopidogrel therapy followed
by withdrawal leads to increased
platelet activity compared with
pre-treatment values in pati-Table 1 Inclusion and Exclusion Criteria
Inclusion criteria
Age 30–80 yrs
Coronary artery disease
Chronic stable angina
Canadian Cardiovascular Score 1 to 3 with prior angiographic evidence
of >50% stenosis in at least 1 major coronary artery
Or
History of prior myocardial infarction
Preserved left ventricular systolic function
Or
Peripheral arterial disease
Stable intermittent claudication and ABPI <0.9
Receiving 75 mg aspirin and statin
Exclusion criteria
Age >80 yrs
Unable to give informed consent
Unstable symptoms over the preceding 3 months
Clinical symptoms of heart failure
Rest pain or ulceration
Known allergy or contraindications to clopidogrel (16)
Liver impairment: aspartate aminotransferase, alkaline phosphatase,
or gamma-glutamyl transferase >3 times upper limit of normal
Platelet count <140  109/l
Neutrophil count <1.5  109/l
Abnormal renal function: creatinine>2 times upper limit of normal, on screening
Bleeding diathesis
Participation in another CTIMP in preceding 3 months
Currently taking
Antiplatelet or anticoagulant drugs other than aspirin
Omeprazole or esomeprazole
ABPI ¼ ankle-brachial pressure index; CTIMP ¼ clinical trial of an investigational medicinal product.ents with stable coronary artery disease (CAD) or PAD.
Methods
Patients. One hundred seventy-one patients were recruited
between June 8, 2009, and May 30, 2012. Patients were
identiﬁed from prospectively gathered databases and from
cardiac and claudication clinics. Comorbidity and medica-
tions were documented. Ethical approval was obtained
(NOSRES 08/S0801/087), and each patient gave written
informed consent. The trial was registered (ISRCTN77887299),
approved by Medicines and Healthcare Products Regulatory
Agency (EudraCT 2007-007638-21), and conducted accor-
ding to Good Clinical Practice.
This was a randomized, placebo-controlled, double-blind
study. Inclusion and exclusion criteria are shown in Table 1.
Patients were allocated to clopidogrel 75 mg daily (diluted
with Lactose PhEur and encapsulated) or indistinguishable
placebo capsules containing Lactose PhEur 540 mg (Tay-
side Pharmaceuticals, Dundee, Scotland) for 30 days
according to a computer-generated minimization program
to balance age, sex, and smoking status (16). All patients
received appropriate risk factor treatment including statin
and 75 mg aspirin daily throughout the study and were
followed up for 28 days after cessation of clopidogrel/
placebo. Participants were randomized just after the base-
line blood sample and awaited instructions to conﬁrm their
blood proﬁle was within safe limits (17) before commencing
study medication.
Outcomes. The primary outcome measure was ADP-
stimulated platelet ﬁbrinogen binding, with 6 pre-speciﬁed
secondary outcome measures: ADP-stimulated platelet
P-selectin expression, unstimulated platelet ﬁbrinogen bin-
ding, and ADP-stimulated platelet aggregation (at 2
concentrations: 5 and 10 mmol/l) recorded at both maximum
and at 6 min.
Samples and assays. Blood samples were taken in the
morning at: 1) baseline, 24 h before commencing clopi-
dogrel or placebo; 2) on treatment, just before discontinu-
ation of clopidogrel or placebo (day 28  2), between 1 to 4
h after ingestion of drug; 3) 7 days after drug discontinua-
tion; 4) 14 days after discontinuation; and 5) 28 days after
discontinuation.
PLATELET ACTIVATIONMARKERS. Platelet ﬁbrinogen binding
with and without stimulation with ADP (10 mmol/l)
or thrombin receptor-activating-peptide (10 mmol/l),
and platelet P-selectin (CD62P) expression with andwithout ADP (10 mmol/l), were assayed in diluted whole
blood samples by ﬂow cytometry (18); intra-assay coefﬁcient
of variation was <10%. Light transmission aggregometry
was performed in platelet-rich plasma with ADP (Sigma-
Aldrich, St. Louis, Missouri) 5 and 10 mmol/l and arach-
idonic acid (Alpha Laboratories, Hampshire, United
Kingdom) 1.5 mmol/l (19). Von Willebrand factor antigen
was measured in plasma by in-house enzyme-linked
immunosorbent assay, as previously described (20), with an
interassay coefﬁcient of variation 9.0%.
Statistical analysis. Based on data from a previous trial
(18), to detect a difference of 10 percentage units in ADP-
induced ﬁbrinogen binding with a standard deviation of
25 U, using a 1-sided t test, a sample size of 78 participants
per group was required (assuming 80% power and a 5%
signiﬁcance level).
Descriptive results were produced for all outcomes, but
statistical testing was only performed for the primary and
secondary outcomes. The primary research question was
addressed using a mixed model procedure, xt-mixed in
Stata (21), using 7 models, 1 for each primary and
secondary outcome measure, excluding the on-treatment
timepoint but including baseline and 7, 14, and 28 days
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235after treatment. An indicator of randomized group was
included as an independent variable in each model. The
effect of patient was treated as a random effect and results
were adjusted for the minimization variables (age, sex, and
smoking status) and diabetes mellitus. Timepoint was
included as a panel variable, and interaction between time
and randomized group was also included. Unstimulated
ﬁbrinogen binding was not normally distributed so it was
log transformed before analysis.
For secondary analyses, baseline and on-treatment values
for the clopidogrel group were compared using paired t tests
(Wilcoxon test for unstimulated ﬁbrinogen binding).Figure 1 CONSORT Diagram of Flow of Participants
CONSORT ¼ Consolidated Standards of Reporting Trials; MI ¼ myocardial infarction; NSAResults
One hundred seventy-one participants were recruited; 159
participants attended all visits and were included in the main
analyses (Fig. 1). The clopidogrel and placebo groups were
similar with respect to age, sex, smoking status, and medical
history (Table 2). Compliance was good, with only 2
patients missing >2 capsules (placebo).
Effect of clopidogrel/placebo (pre-treatment versus
on-treatment sample). In the clopidogrel group, the
primary outcome (ADP-stimulated platelet ﬁbrinogen
binding) (Fig. 2) and all secondary outcomes, exceptID ¼ nonsteroidal anti-inﬂammatory drug; SAE ¼ serious adverse event(s).
Table 2 Patient Demographics by Randomized Group
Clopidogrel
(n ¼ 81)
Placebo
(n ¼ 81)
Sex
Male 68 (84) 68 (84)
Female 13 (16) 13 (16)
Smoking status
Nonsmoker 18 (22) 18 (22)
Current/ex-smoker 63 (78) 63 (78)
Diabetes mellitus 8 (10) 6 (7)
Peripheral arterial disease 23 (28) 13 (16)
Coronary artery disease 70 (86) 72 (89)
CAD initial presentation
MI 44 49
Angina 26 23
Prior revascularization for CAD
PCI 62 65
CABG 7 5
Hypertension 27 (33) 25 (31)
ACE inhibitors 57 (70) 56 (69)
Beta-blockers 52 (64) 58 (72)
Age, yrs 64.3  8.0 [81] 65.2  9.0 [81]
Body mass index, kg/m2 29.7  4.7 [81] 29.2  4.0 [80]
Values are n (%), n, or mean  SD [n].
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypass graft surgery; CAD ¼
coronary artery disease; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
Figure 3
ADP-Stimulated Platelet P-Selectin Expression
in the Placebo and Clopidogrel Groups
Boxplots with bars indicate median, boxes represents 25th to 75th percentiles
(interquartile range [IQR]), and whiskers indicate upper and lower limits, with
outliers beyond 1.5  IQR from the 25th to 75th percentiles. Abbreviations as in
Figure 2.
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236unstimulated ﬁbrinogen binding, were statistically signiﬁ-
cantly lower on treatment than at baseline (p < 0.0001)
(Fig. 3, Tables 3 and 4).Of the othermeasures, only thrombin
receptor-stimulating peptide–stimulated ﬁbrinogen binding
was reduced (Online Table 1). In the placebo group, platelet
outcomes remained at levels similar to baseline.Figure 2
ADP-Stimulated Platelet Fibrinogen Binding in the
Placebo and Clopidogrel Groups
Boxplots with bars indicate median, boxes represents 25th to 75th percentiles
(interquartile range [IQR]), and whiskers indicate upper and lower limits, with
outliers beyond 1.5  IQR from the 25th to 75th percentiles. ADP ¼ adenosine
diphosphate 10 mmol/l; Baseline ¼ pre-treatment sample; Clop ¼ clopidogrel;
Plac ¼ placebo; Treat ¼ on-treatment sample; 7d ¼ 7 days after treatment
cessation; 14d ¼ 14 days after treatment cessation; 28d ¼ 28 days after treat-
ment cessation.Effect of cessation. By 7 days, all outcomes had returned to
baseline levels. Results for the clopidogrel and placebo groups
remained similar at each of the post-treatment timepoints
(Figs. 2 and 3, Tables 3 and 4). The mixed model analyses
(Table 5) showed no statistically signiﬁcant differences in the
overall pattern of results between the clopidogrel and placebo
groups for any of the primary or secondary outcome measures
(p > 0.05). There was no evidence for a treatment-time
interaction effect in any of the models, indicating that the
results were stable over time.
Discussion
This study has shown no evidence of a rebound effect after
cessation of short-term clopidogrel therapy in patients with
stable CAD or PAD. Importantly, this is the ﬁrst study to
allow comparison of pre- and post-treatment activity for 1
month in stable patients and also to include a placebo group,
while comprehensively assessing a range of markers of
platelet activation and aggregation.
As expected, clopidogrel therapy was associated with a
signiﬁcant reduction in ADP-stimulated ﬁbrinogen binding,
P-selectin expression, and platelet aggregation. All platelet
outcomes returned to baseline by 1 week after cessation of
clopidogrel and remained stable at the 14- and 28-day
timepoints. Importantly, there were no statistically signiﬁ-
cant differences overall between the clopidogrel and placebo
groups after treatment.
A number of small studies showed apparent increases in
platelet activity after planned cessation of clopidogrel in
patients with diabetes mellitus (9) and/or stable CAD
(11,12). Among patients stopping clopidogrel 12 months
after stent insertion, Mylotte et al. (12) found a peak in light-
transmission platelet aggregation at 1 month after cessation
Table 3 Results of Primary and Secondary Outcome Measures: Platelet Activation Markers by Flow Cytometry in Placebo and Clopidogrel Groups at Each Time Point
Baseline On Treatment 7 Days Post-Treatment 14 Days Post-Treatment 28 Days Post-Treatment
Clop Placebo Clop Placebo Clop Placebo Clop Placebo Clop Placebo
ADP-stimulated
ﬁbrinogen binding, %
73.9
(63.6–80.6)
[81]
71.3
(59.4–79.8)
[81]
30.9*
(20.8–41)
[79]
72.1
(57.1–79.2)
[78]
69.2
(54.8–74.9)
[79]
74.1
(60.2–83.6)
[77]
75.6
(63.2–81.8)
[78]
69.4
(59.9–81.1)
[77]
77.3
(65.0–82.2)
[80]
73.2
(60.4–81.4)
[77]
Unstimulated
ﬁbrinogen binding, %
1.31
(0.71–2.16)
[81]
1.24
(0.75–1.97)
[81]
1.24
(0.72–2.09)
[79]
1.25
(0.62–2.25)
[78]
1.46
(0.65–2.51)
[79]
1.5
(0.68–2.45)
[77]
1.51
(0.70–2.96)
[79]
1.6
(0.75–2.77)
[77]
1.48
(0.62–2.33)
[80]
1.34
(0.82–2.65)
[77]
ADP-stimulated
platelet P-selectin, %
24.4
(17.2–33.3)
[81]
21.4
(13.7–30.0)
[80]
5.91*
(2.72–9.51)
[77]
20.5
(14.0–30.6)
[77]
20.8
(13.7–28.2)
[78]
21.5
(13.3–32.5)
[76]
22.2
(15.6–29.8)
[78]
21.8
(14.3–29.6)
[77]
23.0
(14.4–34.7)
[80]
18.8
(12.9–29.5)
[77]
Values are median (interquartile range) [n]. *On-treatment versus baseline, paired t test p < 0.0001.
ADP ¼ adenosine diphosphate; Clop ¼ clopidogrel; IQR ¼ interquartile range; max ¼ maximum.
Table 4 Results of Secondary Outcome Measures: Light Transmission Aggregometry in Placebo and Clopidogrel Groups at Each Time Point
Baseline On Treatment 7 Days Post-Treatment 14 Days Post-Treatment 28 Days Post-Treatment
Clop Placebo Clop Placebo Clop Placebo Clop Placebo Clop Placebo
ADP 5 mmol/l
aggregation max, %
55.6  10.9
[81]
53.1  9.6
[81]
34.0*  11.0
[80]
52.1  12.2
[77]
52.4  9.9
[80]
53.4  9.6
[77]
55.6  10.1
[78]
53.8  9.7
[77]
54.1  9.1
[79]
53.3  10.7
[77]
ADP 5 mmol/l
aggregation 6 min, %
48.1  13.4
[81]
45.0  13.5
[81]
15.6*  12.1
[79]
44.4  13.6
[77]
42.8  11.7
[80]
45.7  12.3
[77]
48.7  12.2
[78]
45.8  13.1
[77]
46.5  11.0
[79]
45.2  13.8
[77]
ADP 10 mmol/l
aggregation max, %
64.1  10.8
[81]
61.8  9.1
[81]
42.7*  12.7
[80]
60.7  12.4
[77]
60.8  9.6
[80]
61.4  9.6
[77]
62.5  10.5
[78]
63.1  11.1
[77]
62.3  10.2
[79]
61.7  11.0
[77]
ADP 10 mmol/l
aggregation 6 min, %
60.3  11.8
[81]
57.8  11.1
[81]
25.7*  15.5
[79]
56.8  13.0
[77]
55.4  10.6
[80]
57.4  11.2
[77]
59.6  11.7
[78]
59.2  12.0
[77]
59.1  11.2
[79]
57.6  12.7
[77]
Values are median  SD [n]. *On-treatment versus baseline, paired t test p < 0.0001.
Abbreviations as in Table 3.
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238of treatment compared with 3 months, whereas a study by
Diehl et al. (11) found increased whole blood aggregation at
2 and 6 weeks compared with 17 weeks. However, none of
these studies included a pre-treatment baseline.
Consistent with our ﬁndings, in crossover studies of
P2Y12 inhibitors for stable CAD patients (22) or stable
CAD with diabetes (23), when pre- and post-treatment
platelet aggregation were assessed there was no signiﬁcant
difference from baseline at 7 to 10 days after withdrawal.
Similarly, a small placebo-controlled study involving healthy
subjects observed no increases in a comprehensive range of
platelet tests after discontinuation of clopidogrel compared
with baseline (24).
In stable CAD patients, 6 to 12 months after drug-eluting
stent insertion, ADP aggregation showed recovery up to 1
week after discontinuation of clopidogrel, but values
remained steady out to 4 weeks (13,25). In a larger study of
200 stable CAD patients 12 months after stenting, whole
blood aggregation reached a plateau by 10 days after stop-
ping, and remained stable at 45 and 90 days (26).
Study limitations. The main limitation of the present study
was that patients received clopidogrel for only 1 month, so
chronic changes may have been missed. It has been postu-
lated that long-term clopidogrel therapy could lead to
increased sensitivity of the P2Y12 receptor through increased
coupling or expression (27). However, clinical events have
been shown to occur more frequently in patients who
discontinued clopidogrel within 1 month of commencement
(28). Furthermore, given the half-life of platelets and the
irreversible inhibition by clopidogrel, it is highly unlikely that
we have missed an earlier or a later rebound effect. It is
important to note that all participants had stable CAD or
PAD and were pre-dominantly male and smokers, with
a minority of diabetic patients. The results are not general-
izable to the whole population and are not of relevance to
patients who have sustained a recent acute thrombotic event.Conclusions
The ﬁndings of this study provide reassurance that there is
no evidence of a platelet rebound effect when clopidogrel is
withdrawn in patients with stable CAD or PAD.
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